(R)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride | 459133-43-8

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苯丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride
• 英文别名: 4-bromo-D-phenylalanine methyl ester hydrochloride；H-D-Phe(4-Br)-OMe.HCl；methyl (2R)-2-amino-3-(4-bromophenyl)propanoate;hydrochloride
• CAS: 459133-43-8
• 化学式: C₁₀H₁₂BrNO₂*ClH
• 分子量: 294.576
• InChiKey: MCYQWPUGHHRKME-SBSPUUFOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.91
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 N-叔丁基氧基羰基-氨基-4,4-联苯-R-丙氨酸甲酯
  参考文献：
  名称：

  一种AHU377钙盐的合成方法

  摘要：

  本发明公开了一种AHU377钙盐的合成方法，将4‑溴‑D‑苯丙氨酸与氯化亚砜反应，所得的4‑溴‑D‑苯丙氨酸甲酯盐酸盐与BOC酸酐反应后，再与苯基溴化镁反应得到的 N‑叔丁基氧基羰基‑氨基‑4,4‑联苯‑R‑丙氨酸甲酯，其与硼氢化钠反应后，再与乙氧甲酰基亚乙基三苯基膦反应得 (4R)‑5‑[1,1'‑联苯]‑4‑基‑4‑[[叔丁氧羰基]氨基]‑2‑甲基‑2‑戊烯酸乙酯，再与氢氧化锂反应，加氢催化后与氯化亚砜反应得到(2R,4S)‑5‑([1,1‑联苯基)‑4‑氨基‑2‑甲基戊酸乙酯盐酸盐，再将其与氯化钙和丁二酸酐搅拌反应得到本产品。步骤相对简单，反应条件比较温和，纯度高，收率高。

  公开号：

  CN108299226A
• 作为产物：
  描述：

  甲醇 、 D-4-溴苯丙氨酸 在 氯化亚砜 作用下， 生成 (R)-2-amino-3-(4-bromophenyl)propionic acid methyl ester hydrochloride
  参考文献：
  名称：

  铑通过氧杂双环烯烃的不对称开环-内酯化级联催化铑催化对映选择性合成恶嗪酮。

  摘要：

  铑催化的氧杂双环烯烃的不对称开环反应是合成手性杂环的有效方法。我们证明手性催化剂与手性氨基酸衍生的前亲核试剂的成对组合导致非对映体羟基酯的立体发散合成。有利的构象偏好诱导一种非对映异构体随后的内酯​​化，从而导致恶二酮的高度对映选择性合成。

  DOI：

  10.1021/acs.orglett.9b02819

文献信息

• HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20160024031A1

  公开（公告）日：2016-01-28

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

  描述了异环化合物，这些化合物是溶血磷脂酸受体配体，可用于治疗溶血磷脂酸受体依赖性疾病和状况，包括但不限于涉及纤维化的疾病，如心脏、肾脏、肝脏和肺的纤维化以及硬化病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼病，如涉及视网膜变性的疾病；神经疾病，如瘙痒和疼痛。这些化合物的非限制性例子包括(RS)-3-环丙基-2-4-[3-甲基-4((R)-1-苯基-乙氧羰基氨基)-异恶唑-5-基]-苄氧基}-丙酸和(R)-1-(4′-5-[1-(2-氯-苯基)-乙氧羰基氨基]-4-氟-吡唑-1-基}-2-氟-联苯-4-基)-环丙烷甲酸。
• SUBSTITUTED BIARYL ALKYL AMIDES
  申请人：BioTheryX, Inc.

  公开号：US20130102649A1

  公开（公告）日：2013-04-25

  Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.

  本文披露了替代的联苯烷基酰胺化合物，合成替代的联苯烷基酰胺化合物的方法，以及利用替代的联苯烷基酰胺化合物治疗疾病和/或症状的方法。
• Heterocyclic compounds useful in the treatment of disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US10000459B2

  公开（公告）日：2018-06-19

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

  所述杂环化合物是溶血磷脂酸受体配体，可用于治疗溶血磷脂酸受体依赖性疾病和病症，包括但不限于涉及纤维化的疾病，如心脏、肾脏、肝脏和肺部纤维化以及硬皮病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼部疾病，如涉及视网膜变性的疾病；神经疾病，如瘙痒和疼痛。这些化合物的非限制性实例包括 (RS)-3-Cyclopropyl-2-4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}- 丙酸和 (R)-3-Cyclopropyl-2-4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}- 丙酸。丙酸和(R)-1-(4′-5-[1-(2-氯苯基)-乙氧羰基氨基]-4-氟吡唑-1-基}-2-氟联苯-4-基)-环丙烷羧酸。
• Heterocyclic Compounds Useful In The Treatment of Disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20180297962A1

  公开（公告）日：2018-10-18

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.
• Heterocyclic Compounds Useful In The Treatment Of Disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20190135767A1

  公开（公告）日：2019-05-09

  A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.